A caregiver and physician perspective on the role of vosoritide in the treatment of achondroplasia: an interview with Mary Andrews and Melita Irving

Abstract

Mary Andrews is one of the co-founders of The MAGIC Foundation (IL, USA) and Melita Irving is a clinical geneticist from Guy’s and St Thomas’ NHS Foundation Trust (London, UK) and they are speaking with Rachel Jenkins (Publishing Manager) about achondroplasia and approved treatment, vosoritide. They discuss the impact vosoritide will have on unmet needs in the treatment for achondroplasia.